A phase 1 study to evaluate the safety and LDL cholesterol-lowering effects of RG7652, a fully human monoclonal antibody against proprotein convertase subtilisin/kexin type 9
Baruch, Amos, Luca, Diana, Kahn, Robert S., Cowan, Kyra J., Leabman, Maya, Budha, Nageshwar R., Chiu, Cecilia P.C., Wu, Yan, Kirchhofer, Daniel, Peterson, Andrew, Davis Jr, John C., Tingley, WhittemorLangue:
english
Journal:
Clinical Cardiology
DOI:
10.1002/clc.22687
Date:
March, 2017
Fichier:
PDF, 1.29 MB
english, 2017